You are here
GSK aims to file up to 20 new drugs for approval by 2020
[LONDON] GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.
Britain's biggest drugmaker is trying to boost low investor expectations for its product pipeline by hosting its first research and development day in more than a decade.
The company highlighted advanced and early-stage projects in respiratory medicine, immunology, oncology, vaccines, HIV and other infections, and rare diseases.